MX2024010925A - Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple - Google Patents

Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple

Info

Publication number
MX2024010925A
MX2024010925A MX2024010925A MX2024010925A MX2024010925A MX 2024010925 A MX2024010925 A MX 2024010925A MX 2024010925 A MX2024010925 A MX 2024010925A MX 2024010925 A MX2024010925 A MX 2024010925A MX 2024010925 A MX2024010925 A MX 2024010925A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
isatuximab
agents
treatment
combination
Prior art date
Application number
MX2024010925A
Other languages
English (en)
Spanish (es)
Inventor
Blondel Marielle Chiron
Alexandre Desjonqueres
Zandra Karina Klippel
Marco Meloni
Angela Virone-Oddos
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of MX2024010925A publication Critical patent/MX2024010925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024010925A 2022-03-07 2024-09-06 Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple MX2024010925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317253P 2022-03-07 2022-03-07
PCT/US2023/063869 WO2023172917A1 (en) 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
MX2024010925A true MX2024010925A (es) 2025-02-10

Family

ID=85800365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010925A MX2024010925A (es) 2022-03-07 2024-09-06 Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple

Country Status (10)

Country Link
US (1) US20250177519A1 (enExample)
EP (1) EP4489766A1 (enExample)
JP (1) JP2025509343A (enExample)
KR (1) KR20250029015A (enExample)
CN (1) CN119486744A (enExample)
AU (1) AU2023231217A1 (enExample)
CA (1) CA3245572A1 (enExample)
IL (1) IL315471A (enExample)
MX (1) MX2024010925A (enExample)
WO (1) WO2023172917A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US11221328B2 (en) * 2017-03-08 2022-01-11 Nantcell, Inc. Hypoxic NK cells and methods therefor
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN114867485A (zh) 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer

Also Published As

Publication number Publication date
KR20250029015A (ko) 2025-03-04
EP4489766A1 (en) 2025-01-15
CA3245572A1 (en) 2023-09-14
JP2025509343A (ja) 2025-04-11
AU2023231217A1 (en) 2024-10-17
CN119486744A (zh) 2025-02-18
US20250177519A1 (en) 2025-06-05
WO2023172917A1 (en) 2023-09-14
IL315471A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
Spaggiari et al. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2
Hüber et al. IL‐12/15/18‐preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation
Blanco et al. Immunomodulatory effects of bone marrow versus adipose tissue‐derived mesenchymal stromal cells on NK cells: Implications in the transplantation setting
Tao et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+ CD56+ cells and downregulating regulatory T cells as well as IL-35
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
MY206158A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
MX2021004579A (es) Métodos para trasplante de células madre hematopoyéticas alogénicas.
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
Laroni et al. IL-27 imparts immunoregulatory function to human NK cell subsets
MX2019003543A (es) Anticuerpos que se fijan al interleucina-2 y sus usos.
Servais et al. Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
PH12021552743A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
MX2023010812A (es) Composiciones y metodos para tratar la nefritis lupica.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2022005973A (es) Inhibidores de akt para mejorar la persistencia de celulas t quimericas.
WO2022026902A3 (en) Chimeric proteins and methods of use for treatment of central nervous system disorders
MX2025012790A (es) Metodos de administracion de anticuerpos que se unen a la interleuquina 13
PH12023552792A1 (en) Combination therapies for the treatment of cancer
ZA202406357B (en) Compositions and methods for depletion of diseased hematopoietic stem cells
Moustaki et al. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
MX2022009885A (es) Composiciones y metodos para el trasplante alogenico.
PH12021550417A1 (en) Compositions and methods for controlled ovarian stimulation
Budde et al. An alternative for extracorporeal photopheresis: 8‐methoxypsoralen and UVA‐treated leucocytes from allogeneic donors improve graft‐versus‐host disease in mice